• Prochlorperazine-Induced Hemidystonia Mimicking Stroke

  2026-09-03

  This case report describes acute unilateral dystonia after newly initiated Prochlorperazine that closely resembled ischemic stroke in a pregnant patient. Its main contribution is a practical diagnostic framework: continue urgent stroke evaluation while using medication history, evolving extrapyramidal signs, serial examinations, neuroimaging, and response to diphenhydramine to identify a potentially reversible stroke mimic.

• Toremifene vs Tamoxifen in Advanced Breast Cancer

  2026-09-03

  This Cochrane review directly compared toremifene with tamoxifen across tumor response, disease progression, survival, and treatment-related adverse events in advanced breast cancer. The available randomized evidence did not demonstrate a consistent efficacy or safety advantage for either endocrine agent, while incomplete trial reporting limits conclusions about equivalence.

• Thiamet G for O-GlcNAcylation Workflows

  2026-09-02

  Thiamet G is a potent, selective O-GlcNAcase inhibitor for controlled elevation of protein O-GlcNAcylation in neuronal, leukemia, and osteogenic experiments. This guide connects practical dosing, metabolic readouts, tau assays, and Wnt-driven bone research while emphasizing controls and troubleshooting.

• Nicotinamide Riboside Chloride in RGC Research

  2026-09-02

  Use Nicotinamide Riboside Chloride (NIAGEN) as a controlled NAD+ metabolism variable alongside chemically defined iPSC-to-RGC differentiation. This workflow separates lineage-patterning effects from energy and stress phenotypes, supporting metabolic dysfunction research and neurodegenerative disease models without implying an unvalidated therapeutic effect.

• SMPD4, Ceramide, and Primary Cilia in Brain Development

  2026-09-01

  The 2024 Development study connects SMPD4-dependent ceramide production with primary cilium integrity, neural progenitor survival, and cerebellar development. By combining a mouse model with SMPD4-deficient human induced pluripotent stem cells, the authors show that ceramide deficiency is a mechanistic link between sphingolipid metabolism and neurodevelopmental disease.

• Apigenin: From Network Signal to Assay Design

  2026-09-01

  Apigenin research is moving beyond broad claims about flavonoid activity toward mechanism-resolved assay design. This guide connects network-based Alzheimer’s disease evidence with HDAC, apoptosis, ROS, and DNA-damage readouts while defining practical controls and interpretation limits.

• Esflurbiprofen and SERT-nNOS in Rapid Antidepressant Action

  2026-08-31

  The reference study identifies esflurbiprofen as a fast-onset antidepressant candidate by combining mBRET-based screening with behavioral, imaging, pharmacodynamic, and molecular analyses. Its central finding is that disrupting the SERT-nNOS complex in the dorsal raphe nucleus may relieve 5-HT1A autoreceptor-mediated negative feedback and rapidly restore serotonergic signaling in stress-exposed mice.

• Tubastatin A: From HDAC6 Target to Cell-Death Assays

  2026-08-31

  Tubastatin A is a selective HDAC6 inhibitor whose value extends beyond target engagement: it can help resolve how pyroptosis, necroptosis, inflammation, and myocardial dysfunction are connected. This article translates porcine cardiac-arrest evidence into practical assay design and interpretation.

• Ruxolitinib–oHSV Therapy Reprograms Sarcoma Immunity

  2026-08-30

  The reference study introduces a 46-parameter spectral flow cytometry panel to resolve lymphoid and myeloid immune changes in poorly infiltrated murine malignant peripheral nerve sheath tumors. It shows that ruxolitinib combined with repeated oncolytic herpes simplex virus dosing extends immune remodeling beyond previously described T-cell changes, increasing activated germinal-center B cells and cytokine-producing CD4 populations.

• RIPostC, Ketone Bodies, and Ferroptosis in Stroke

  2026-08-29

  The 2024 ACS Chemical Neuroscience study identifies ketone-body production as a mechanistic connection between remote ischemic postconditioning and neuroprotection after ischemic stroke. Its rat and HT22-cell experiments link improved energy metabolism with reduced lipid peroxidation, preserved GPX4, lower ACSL4 expression, and reduced iron accumulation, while also defining important limits for translating ketone-body findings to 3-hydroxybutyrate-specific workflows.

• TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas

  2026-08-28

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma cell proliferation, and resistance to dopamine-agonist treatment. Its combination of CRISPR screening, ubiquitination analysis, and NanoBiT-based drug screening links TRIM21 suppression by Quisinostat with reduced tumor progression and improved drug sensitivity, while also highlighting important translational limitations.

• Network Medicine Identifies Apigenin for Alzheimer’s

  2026-08-28

  The 2025 reference study uses network medicine to rank flavonoids by proximity to Alzheimer’s disease targets and identifies Apigenin as the strongest candidate among four experimentally tested compounds. Its cellular validation connects Apigenin with mitochondrial protection, reduced apoptosis, AKT/NF-κB pathway modulation, and attenuation of microglia-associated neuroinflammation, while also defining important limits for translational interpretation.

• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-08-27

  The 2024 Nature Communications study identifies SmD2 acetylation as a regulatory connection between core spliceosome stability, BRCA1/FANC cassette-exon usage, and PARP-inhibitor response in hepatocellular carcinoma. Its findings support a model in which p300, HDAC2, and spliceosome-dependent DNA-repair regulation can be evaluated as a combined therapeutic axis, while remaining preclinical and HCC-specific.

• Sisomicin Activity Against Clinical Isolates

  2026-08-27

  This 1975 study evaluated Sisomicin against 565 clinical isolates and established a comparative susceptibility profile similar to gentamicin and tobramycin, with particularly strong activity against most Gram-negative bacilli. Its dilution-based design also identified an important resistance relationship: isolates resistant to gentamicin and tobramycin were generally resistant to Sisomicin, whereas many remained susceptible to amikacin.

• (5Z)-7-Oxozeaenol: Selective TAK1 Inhibitor

  2026-08-26

  (5Z)-7-Oxozeaenol is a potent, selective TAK1 inhibitor for testing IL-1-linked NF-κB and JNK/p38 MAPK signaling. Product and primary-study evidence support its use as a biochemical reagent in inflammation models, while metabolic-stress applications require pathway-specific validation.

699 records 6/47 page Previous Next First page 上5页 678910 下5页 Last page